Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

January 05, 2015
ALCHEMIST Erlotinib
Lung Cancer
Maria Quejada, MD

Naperville, Plainfield

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Sponsor: Alliance for Clinical Trials in Oncology

https://clinicaltrials.gov/ct2/show/NCT02193282?term=Erlotinib+Hydrochloride+in+Treating+Patients+With+Stage+IB-IIIA+Non-Small+Cell+Lung+Cancer+That+Has+Been+Completely+Removed+by+Surgery&rank=1

  • Previously registered to ALCHEMSIT A151216, with the result of lung cancer harboring an EGFR exon 19 deletion or L858R mutation
  • Complete recovery from surgery and standard post-operative therapy (if required); the time between date of surgery and randomization must be at least 28 days and no more than 90 days if no adjuvant chemotherapy was administered, 180 days if adjuvant chemotherapy was administered, and 240 days if adjuvant chemotherapy and radiation therapy was administered

10-12 years

Accepting Participants
Interventional
III
Kathy Seymour, BSN
630-646-6050
630-646-6110
630-646-6075